Conditions: Non-Hodgkins Lymphoma
Keywords: NHL CC5013 Non-Hodgkins Lymphoma revlimid cc-5013 celgene
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 43
Healthy volunteers: no

Brief summary:
Subjects who qualify will receive lenalidomide daily on days 1-21 of every 28-day cycle. Treatment will continue for up to 52 weeks or until disease progression; subjects who achieve a Complete Response (CR) will receive an additional 2 cycles of treatment prior to discontinuation. Subjects will be followed for progression free survival following discontinuation from the treatment phase

Detailed description:

Arms:
arm 1: Participants received single-agent lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed.

Interventions: intervention 1: Lenalidomide
Intervention descriptions: intervention 1: None

Protocol document: